Compounded hormone therapy is a custom-prepared alternative to commercially manufactured hormone products. Current guidance from major medical bodies indicates it is intended for specific situations rather than routine first-line use: most often when a patient reacts to an ingredient in an approved product, or when a needed dose or dosage form is not commercially available.
This guide summarizes current guidance and published research on formulation choices, delivery routes, and applicable regulatory limits. It is informational and is not a recommendation for any individual patient.
Where Compounded Hormone Therapy Fits
No custom-compounded hormone preparation is FDA-approved. That single fact shapes every recommendation below.
The National Academies of Sciences, Engineering, and Medicine reviewed the evidence in July 2020. They concluded that the efficacy and effectiveness data supporting compounded hormone therapy come largely from low-quality sources. The report recommended limiting use to two situations: a documented allergy to an ingredient in an approved product, and a documented need for a dose or dosage form that no approved product provides.
ACOG Clinical Consensus No. 6, published November 2023, reached a similar position: compounded preparations should not be prescribed routinely where an approved formulation exists, and patients who request them should be told the FDA has not reviewed these products. The 2022 Hormone Therapy Position Statement from The Menopause Society, still the current version, likewise treats compounded products as carrying safety uncertainty that approved products do not.
One recent development is worth noting. In November of 2025, the FDA announced it would remove boxed warning language on cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products, following a July 2025 advisory panel and a literature review. The first six products received approved labeling changes in 2026. The endometrial cancer warning remains on systemic estrogen-only products. This change applies to approved products, not to compounded ones.
Compounding still has a defined place. The gaps it fills are practical: an allergen a patient cannot tolerate, a strength that falls between commercial increments, or a combination that is not sold as a single product.
Bi-Est: Combining Estradiol and Estriol
Bi-Est is a compounded combination of estradiol (E2) and estriol (E3), commonly prepared in an 80:20 ratio of estriol to estradiol, or 50:50.
A word of caution about a claim that circulates widely: estriol is often described as selectively binding estrogen receptor beta, which is said to concentrate its effect on vaginal and urinary tissue while sparing breast and uterine tissue. Published receptor binding data do not support this. A review in Mayo Clinic Proceedings reports that estriol has the weakest binding affinity of the three main estrogens for either receptor, and a 2017 comparative study found compounded estriol behaved much like reference estriol, without the selectivity the marketing claim describes. Estriol is a weaker estrogen. That is the accurate short version.
Estriol has a USP monograph, which is what permits its use as a bulk substance under section 503A of the Federal Food, Drug, and Cosmetic Act. No FDA-approved estriol product is sold in the United States.
Micronized Progesterone and Synthetic Progestins

When systemic estrogen is prescribed to a patient with a uterus, a progestogen is needed to protect the uterine lining from thickening (endometrial hyperplasia).
Micronized progesterone is structurally identical to the progesterone the body produces. It differs from synthetic progestins such as medroxyprogesterone acetate in a few documented ways. The PEPI trial found a more favorable lipid profile with micronized progesterone than with medroxyprogesterone acetate. A metabolite, allopregnanolone, acts on the same calming brain receptors targeted by common sleep and anxiety medicines, which is why bedtime dosing is standard and why sedation is expected rather than surprising.
Two practical points:
Peanut oil. The FDA label for Prometrium lists peanut oil as an inactive ingredient, and peanut hypersensitivity is a contraindication. This is the clearest example of the documented-allergy exception the NASEM report described. Compounded alternatives use other oil bases. Most of the time, dry powders are used, such as Cellulose for the base, which is plant-based and hypoallergenic.
Topical progesterone. Transdermal progesterone creams have variable absorption and are generally not considered adequate for protecting the uterine lining in a patient taking estrogen. Oral or vaginal routes are used when endometrial protection is the goal.
Delivery Route and Clot Risk
Estrogen taken by mouth passes through the liver before entering general circulation, which increases production of clotting factors and sex hormone-binding globulin. Estrogen absorbed through the skin largely bypasses that step.
Observational evidence supports a difference in clot risk. A 2008 systematic review and meta-analysis in The BMJ found the odds of a first clot were 2.5 times higher in current users of oral estrogen than in non-users, while transdermal users showed 1.2, with a confidence interval crossing 1.0. A 2015 meta-analysis in The Journal of Clinical Endocrinology and Metabolism found oral estrogen carried a higher risk of clots and deep vein thrombosis than transdermal. The Menopause Society’s 2022 statement reflects this, noting that transdermal routes and lower doses may reduce clot and stroke risk.
This evidence is based on observation rather than randomized, and at least one large cohort study of women veterans found no difference. The evidence is consistent, but it has not been tested in a randomized trial.
Sublingual troches are sometimes used for patients who do not tolerate topical bases. Absorption from troches is less predictable than from approved transdermal products.
Testosterone and DHEA in Women
The International Consensus Position Statement on testosterone therapy for women, published in 2019 and endorsed by eleven societies, is clear: the only evidence-based indication is low sexual desire that causes distress (hypoactive sexual desire disorder) in postmenopausal women. The panel found insufficient evidence to support testosterone for fatigue, mood, cognition, bone density, or disease prevention. Long-term safety has not been established beyond 24 months.
No testosterone product is approved in the United States for women, so all use is off-label. The statement advises keeping blood levels within the range seen in healthy premenopausal women. ACOG recommends against pellets, citing limited safety data and the fact that a pellet cannot be removed once placed.
For DHEA, the distinction matters: vaginal DHEA (prasterone) is an approved product for painful intercourse after menopause. At the same time, systemic DHEA is not recommended for low desire in women with normal adrenal function.
Bases and Vaginal Vehicles

Vaginal dryness, irritation, and urinary symptoms after menopause (genitourinary syndrome of menopause) affect a large share of postmenopausal women. Some commercial vaginal preparations contain alcohol, propylene glycol, or parabens, which a subset of patients report as burning or irritation.
Compounding allows those ingredients to be left out. Estriol or estradiol can be prepared in creams or suppositories built on bases selected to avoid a specific known irritant. Hyaluronic acid is sometimes added to vaginal preparations to support tissue hydration, though comparative data on combined preparations are limited.
“The delivery vehicle affects whether a patient stays on therapy,” says Xuan T. Huynh, PharmD, compounding pharmacist-in-charge and founder of WeCare Pharmacy. “When a patient has a documented reaction to a specific ingredient, being able to formulate without it is often what makes continued treatment possible.”
Prescribing FAQs
Is Bi-Est more targeted than estradiol alone?
Not in the way it is often described. Published binding data do not support the receptor selectivity claim made for estriol. Estriol is a weaker estrogen than estradiol, so a combination delivers less total estrogenic activity than an equivalent amount of estradiol. Randomized trials have not established whether that is clinically useful for a given patient.
Can progesterone be compounded without peanut oil?
Yes. Peanut oil is an inactive ingredient in Prometrium, and peanut allergy is a labeled contraindication. Compounded micronized progesterone can be prepared in other oil bases, including medium-chain triglyceride oil, or as capsules or troches. A documented allergy of this kind is one of the two situations the NASEM report identified as appropriate for compounding.
Does transdermal delivery lower clot risk?
Observational studies consistently show lower clot risk with transdermal estrogen than with oral estrogen, and the biological explanation is well described. The evidence is not randomized, and results are not fully uniform across studies, so it is best described as a consistent signal rather than a settled finding.
How should a compounded vaginal prescription be written?
Specify the hormone and concentration (for example, estriol 0.05%), the vehicle, the total quantity, and the frequency of use. Include the reason compounding is needed, such as a documented reaction to a specific excipient, to support the clinical record.
Working With WeCare Pharmacy
WeCare Pharmacy prepares custom hormone formulations for prescribers whose patients cannot use a commercially available product as supplied. Our pharmacists can discuss base selection, available strengths, and what a specific formulation can and cannot be expected to do before a prescription is written.
To review formulation options or discuss a specific case, see our compounding services or contact the pharmacy directly.
This article is for licensed prescribers and is provided for informational purposes. It does not constitute medical advice or a recommendation for any individual patient. Compounded preparations are not FDA-approved.


